Event/Regulatory approval
Completed
Lilly's orforglipron calcium tablet approved for marketing in China
Trajectories
Explore probable futures of this record — up to three arcs with a direction, a probability and a horizon.
Actors and targets
Source
礼来奥氟格列隆钙片获批上市,为国内首个口服GLP-1类减重药物。